Dr. Christopher Swearingen serves as the Vice President of Biometrics at Biosplice Therapeutics, where he leverages his extensive expertise in biostatistics and clinical outcomes research to drive innovative therapeutic developments. With over two decades of experience, Dr. Swearingen has a proven track record in the...
Dr. Christopher Swearingen serves as the Vice President of Biometrics at Biosplice Therapeutics, where he leverages his extensive expertise in biostatistics and clinical outcomes research to drive innovative therapeutic developments. With over two decades of experience, Dr. Swearingen has a proven track record in the design and execution of clinical trials, particularly in the realm of alternative pre-mRNA splicing—a cutting-edge area of research that holds promise for treating a variety of diseases, including those in rheumatology and neuroscience.
At Biosplice, Dr. Swearingen is instrumental in leading key projects that explore the therapeutic potential of small-molecule compounds derived from the modulation of the Wnt signaling pathway. His role involves overseeing the statistical design and analysis of clinical trials, ensuring that robust methodologies are employed to derive meaningful insights from complex datasets. His proficiency in data analysis tools such as SPSS and R enables him to extract valuable information that informs decision-making and enhances the efficacy of clinical outcomes.
Prior to joining Biosplice, Dr. Swearingen was the Associate Director of the Pediatric Biostatistics Program at Arkansas Children's Hospital Research Institute, where he spearheaded community-based clinical trials and fostered collaboration among informatics and analytic teams. His experience in grant writing and scientific writing further complements his ability to communicate complex statistical concepts to diverse stakeholders, making him a pivotal figure in advancing the mission of Biosplice Therapeutics. Through his leadership, the company continues to pioneer novel approaches to therapeutic development, positioning itself at the forefront of biopharmaceutical innovation.
